Evaluation of the effect of krocina in patients with Diminished ovarian reserve

Evaluation of the effect of krocina supplement on the follicular oxidative stress and quality of oocyte and embryo in patients with Diminished ovarian reserve (DOR)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220516054872N1

Enrollment

Registered

2022-06-13

Start date

2022-01-21

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished ovarian reserve.

Interventions

Intervention group: A treatment group consisting of 15 patients with reduced ovarian reserve (based on inclusion and exclusion criteria) received a dose of one Krocina tablet from Sami Pharmacy with a

Eligibility

Sex/Gender

Female

Age

No minimum to 40 Years

Inclusion criteria

Inclusion criteria: History of uterine bleeding and amenorrhea before 40 years FSH <10U/L ? AMH<0.5 – 1.1 ng/ml Infertility without a specific cause

Exclusion criteria

Exclusion criteria: POI patients with 25 40 IU / ml POI patients with 25 40 IU / mlPOF patients with a 4-month period of amenorrhea and <FSH40 Chromosomal disease in each pair Hysterosalpingography, which shows a defective female reproductive system Genetic disorders such as Turner syndrome Patients using alkylating agents or radiation therapy Decreased PTH and aldosterone Patients with hyper or hypothyroidismType I diabetic patients Patients with Cushing's disease or Addison's disease Cases of obesity History of malignant tumor Taking antioxidant-related medications in the last 3 months Use hormone therapy to induce ovulation in the last 2 months History of taking contraceptives in the last 3 months

Design outcomes

Primary

Measure	Time frame
Patients with Diminished ovarian reserve. Timepoint: Measurement of blood FSH, LH and estradiol levels 3 months after taking the drug. Method of measurement: Evaluation of number and quality of oocytes extracted from ovarian stimulation using stereomicroscope, measurement of superoxide desmutase level in follicular fluid by spectrophotometry using SOD Assay Kit, detection of reactive oxygen species in granulosa cells using flow cytometry On DCFH-DA, assay of NRF2 gene expression as a marker of oxidative stress suppression and GDF9 and BMP15 genes as marker of oocyte maturation in granulosa cells by qRT-PCR.	—

Measure

Time frame

Patients with Diminished ovarian reserve. Timepoint: Measurement of blood FSH, LH and estradiol levels 3 months after taking the drug. Method of measurement: Evaluation of number and quality of oocytes extracted from ovarian stimulation using stereomicroscope, measurement of superoxide desmutase level in follicular fluid by spectrophotometry using SOD Assay Kit, detection of reactive oxygen species in granulosa cells using flow cytometry On DCFH-DA, assay of NRF2 gene expression as a marker of oxidative stress suppression and GDF9 and BMP15 genes as marker of oocyte maturation in granulosa cells by qRT-PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hamid nazarian

Shahid Beheshti University of Medical Sciences

hamid.nazarian@gmail.com+98 21 23871

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026